BBIO BridgeBio Pharma Inc
4,654
$27.70
$0.09
(0.32%)
| Watchers | 4,654 |
| 52-Wk Low | $12.75 |
| 52-Wk High | $44.32 |
| Market Cap | $5.2B |
| Volume | 732,570.00 |
| 52-Wk High | $44.32 |
| 52-Wk Low | $12.75 |
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Globe Newswire • about 1 month ago
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression...
Share to Feed
Raymond James initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO Free Report) in a research note issued to investors on Thursday, StockNewsAPI reports. The firm issued an...
Investment analysts at Raymond James started coverage on shares of BridgeBio Pharma (NASDAQ:BBIO Get Free Report) in a research report issued on Thursday, StockNewsAPI reports. The brokerage...
This is a Bullish indicator signaling BBIO's price could rise from here. Traders may explore going long the stock or buying call options...
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ( BridgeBio or the Company ), a commercial-stage biopharmaceutical company focused on genetic diseases...
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO Get Free Report) have received an average rating of Moderate Buy from the twelve brokerages that are covering the company...
This is a signal that BBIO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
In trading on Friday, shares of BridgeBio Pharma Inc (BBIO) crossed below their 200 day moving average of 28.76, changing hands as low as 28.71 per share. BridgeBio Pharma Inc shares are...
BridgeBio Pharma (NASDAQ:BBIO Get Free Report) had its target price dropped by stock analysts at Mizuho from $60.00 to $53.00 in a note issued to investors on Tuesday, Benzinga reports. The...
Investors in BridgeBio Pharma Inc (BBIO) saw new options become available today, for the April 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BBIO...